Abstract |
The anti-arrhythmic efficacy of barucainide, a new class IB anti-arrhythmic agent, was evaluated in an open-label therapeutic study in a total of 15 patients with coronary artery disease. The majority of patients had a history of myocardial infarction. After a 3-day placebo run-in period barucainide was administered at a dose of 150 mg b.d. for 5 days followed by a 4-day placebo wash-out period. 24-h Holter monitorings were recorded in the run-in period, on day 4 of the treatment period, and on day 3 of the wash-out period. In addition, plasma levels were determined in all three periods. Statistical evaluation of the 24-h arrhythmia analyses revealed a decrease of premature ventricular contractions (PVCs) in all treated patients. Before treatment PVCs occurred at a median of 92.4/h (minimum 19/maximum 1537 PVCs/h); this value was reduced during treatment to a median of 7.9 (0/427) PVCs/h (p less than 0.01). A similar result was also found for the couplets which decreased significantly from a median (min/max) of 0.6 (0/11)/h before treatment with barucainide to 0.1 (0/3)/h after treatment (p less than 0.05). In 10 of 15 patients premature ventricular contractions were reduced by more than 80%. Ventricular tachycardia present in 4 of 15 patients was suppressed in all cases. Barucainide had only a slight effect on PQ and QTc intervals, QRS duration, heart rate, and blood pressure.
|
Authors | P Brugger |
Journal | Zeitschrift fur Kardiologie
(Z Kardiol)
Vol. 78
Issue 8
Pg. 510-8
(Aug 1989)
ISSN: 0300-5860 [Print] Germany |
Vernacular Title | Wirksamkeit von Barucainid bei supraventrikulären und ventrikulären Arrhythmien. |
PMID | 2477959
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Pyridines
- barucainide
|
Topics |
- Anti-Arrhythmia Agents
(therapeutic use)
- Cardiac Complexes, Premature
(drug therapy)
- Clinical Trials as Topic
- Coronary Artery Bypass
- Electrocardiography, Ambulatory
- Exercise Test
- Heart Ventricles
(drug effects)
- Humans
- Middle Aged
- Myocardial Infarction
(drug therapy)
- Postoperative Complications
(drug therapy)
- Pyridines
(therapeutic use)
- Tachycardia
(drug therapy)
- Tachycardia, Supraventricular
(drug therapy)
|